KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-Current Assets: 2018-2024

Historic Non-Current Assets for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $255.6 million.

  • Adaptive Biotechnologies' Non-Current Assets fell 16.38% to $209.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.2 million, marking a year-over-year decrease of 16.38%. This contributed to the annual value of $255.6 million for FY2024, which is 1.86% up from last year.
  • According to the latest figures from FY2024, Adaptive Biotechnologies' Non-Current Assets is $255.6 million, which was up 1.86% from $250.9 million recorded in FY2023.
  • Adaptive Biotechnologies' 5-year Non-Current Assets high stood at $520.6 million for FY2021, and its period low was $250.9 million during FY2023.
  • In the last 3 years, Adaptive Biotechnologies' Non-Current Assets had a median value of $255.6 million in 2024 and averaged $267.0 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Non-Current Assets skyrocketed by 33.66% in 2021, and later crashed by 43.44% in 2022.
  • Adaptive Biotechnologies' Non-Current Assets (Yearly) stood at $389.5 million in 2020, then spiked by 33.66% to $520.6 million in 2021, then crashed by 43.44% to $294.5 million in 2022, then decreased by 14.78% to $250.9 million in 2023, then increased by 1.86% to $255.6 million in 2024.